Adenosine and extracellular volume in radiocontrast media-induced nephropathy.
Renal hemodynamic changes could play a key role in radiocontrast media-induced nephropathy (RCIN), although the pathophysiological mechanisms are unclear. We investigated the role of adenosine in RCIN caused by sodium diatrizoate (Urografin, 3 ml/kg) in nitro-L-Arg methyl ester (L-NAME)-hypertensive rats in different hydration states [eight weeks of L-NAME (50 mg/liter) in drinking water; high or low sodium intake for the last two weeks]. In clearance experiments under thiobutabarbital anesthesia in these previously mentioned animals, glomerular filtration rate (GFR), renal blood flow (RBF), and mean arterial pressure (MAP) were measured in the presence or absence of the adenosine A1-receptor antagonist 8-cyclopropyl-1,3-dipropylxanthine (DPCPX, 100 microg/kg bolus plus 10 microg/kg/hr). DPCPX or pretreatment did not change control hemodynamics. Contrast medium caused GFR and RBF to fall significantly in volume-depleted rats (from 0.29 +/- 0.02 to 0.21 +/- 0.02 ml/min/100 g and 5.4 +/- 0.3 to 4.0 +/- 0.4 ml/min, respectively) without change in MAP. In volume-expanded rats, changes were not significant (0.25 +/- 0.01 to 0.24 +/- 0.02 ml/min/100 g and 5.6 +/- 0.3 to 5.3 +/- 0.4 ml/min, respectively). In the volume-depleted rats, changes were prevented by DPCPX (0.27 +/- 0.02 to 0.24 +/- 0.02 ml/min/100 g and 4.8 +/- 0.1 to 5.0 +/- 0.1 ml/min, respectively). The acute hemodynamic effects elicited by contrast medium in L-NAME hypertensive rats thus can be prevented by volume expansion. Adenosine, via A1-receptors, contributes to the adverse effects of contrast media.
Erley
C M
CM
Third Department of Internal Medicine, Eberhard-Karls-Universität, Tübingen, Germany.
Heyne
N
N
Rossmeier
S
S
Vogel
T
T
Risler
T
T
Osswald
H
H
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism*; D000241:Adenosine / Q000032:analysis*; D000818:Animals; D001794:Blood Pressure; D003287:Contrast Media / Q000009:adverse effects*; D004791:Enzyme Inhibitors; D005110:Extracellular Space / Q000737:chemistry; D006400:Hematocrit; D006977:Hypertension, Renal / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism; D007668:Kidney / Q000737:chemistry / Q000378:metabolism; D008297:Male; D019331:NG-Nitroarginine Methyl Ester; D058915:Purinergic P1 Receptor Antagonists; D051381:Rats; D017208:Rats, Wistar; D014867:Water / Q000378:metabolism; D014970:Xanthines / Q000494:pharmacology
D003287:Contrast Media; D004791:Enzyme Inhibitors; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; D014867:Water; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000241:Adenosine; D019331:NG-Nitroarginine Methyl Ester